SOPHIA GENETICS Presents Ground-Breaking Multidisciplinary Research on AI-Driven Patient Strategizing at ESMO 2024 | SOPH stock information

A study focuses on the use of multiple machine learning to identify non-small cell lung cancer patients predicted to benefit most from combination therapy.

Boston and ROLLE, Switzerland, September 14, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-based healthcare technology company and a leader in data-driven medicine, will launch a new study at the European Society of Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, uses advanced AI-driven methods to identify subgroups of patients with stage IV non-small cell lung cancer (NSCLC) who may benefit most from the addition of tremelimumab to durvalumab and chemotherapy.

The study is a retrospective, multicenter study of the Phase 3 clinical trial of POSEIDON (NCT03164616). This trial previously showed that the combination of tremelimumab, durvalumab, and chemotherapy significantly increases progression-free survival (PFS) and overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, leading to approval of this regimen worldwide in 1L mNSCLC. The SOPHiA GENETICS study used sophisticated multi-machine learning models to analyze clinical, biological, genetic and imaging data, identifying subgroups of patients most likely to benefit from combination therapy.

The study highlighted the signatures that identify patients with metastatic non-squamous NSCLC who may experience a higher OS benefit from the addition of tremelimumab to durvalumab plus chemotherapy in the first-line treatment setting. Specifically, wild-type EGFR, wild-type FGFR3, wild-type CDKN2A, KRAS mutations, and STK11 mutations comprising signature elements were identified as being associated with higher OS benefit. These findings may have significant implications for the treatment of NSCLC, as they provide a diagnostic pathway toward a more tailored approach to patient care.

“Our collaboration with AstraZeneca represents a major step forward in personalized oncology. Non-small cell lung cancer remains one of the most challenging cancers to treat due to its complex biology and the late stage at which it is often diagnosed,” said Jurgi Camblong. Ph.D., Co-founder and CEO of SOPHiA GENETICS. “This research uses the power of multivariate data and advanced AI to identify patients who are most likely to benefit from specific treatments. By tailoring treatment strategies to the unique profile of a patient’s multivariate, we aim to improve outcomes and deliver a new hope for those fighting this difficult disease.”

The study will be presented as a poster by Ferdinandos Skoulidis, Department of Thoracic Medicine, University of Texas MD Anderson Cancer Center at ESMO 2024 organized Barcelona, ​​Spain from September 13-17, 2024. His presentation shows the potential of working with the clinical implications of advanced multi-species analysis in identifying the effects of different treatments in cancer.

For more information on SOPHiA GENETICS, visit SOPHIAGENETICS.COMor connect LinkedIn.

About SOPHIA GENETICS
SOPHIA GENETICS (Nasdaq: SOPH) is a cloud healthcare technology company on a mission to expand access to data-driven medicine using AI to deliver world-class care to cancer and rare disease patients around the world. It is the developer of the SOPHiA DDM™ System, which analyzes complex genetic and multi-module data and provides real-time, actionable insights to a wide global network of hospitals, laboratories and pharmaceutical treatment institutes. For more information, visit SOPhiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and are not for use in diagnostic procedures unless otherwise specified. The information in this press release is about products that may or may not be available in different countries and, if used, may or may not receive approval or market approval by a government regulatory agency for different indications of use. Please contact [email protected] for product information appropriate for your country of residence.

SOPHiA GENETICS Forward-Looking Information:
This press release contains statements that include forward-looking statements. All information other than statements of historical fact contained in this press release, including information about our future operating results and financial condition, business strategy, products and technologies, as well as management’s plans and objectives for for future activities, it is to look forward. statement. Forward-looking statements are based on the beliefs and assumptions of our management and information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in forward-looking statements due to various factors, including those described in our filings and United States Securities and Exchange Commission. No assurance can be given that such results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or promise to update these forward-looking statements contained in this press release to reflect any changes in our expectations or any changes in the events, conditions, or circumstances on which such statements are based, except as required to do so. the law. No representations or warranties (expressed or implied) are made as to the accuracy of any such forward-looking statements.

View original content to download multimedia: https://www.prnewswire.com/news-releases/sophia-genetics-presents-ground-breaking-multimodal-research-on-ai-driven-patient-stratification-at-esmo-2024 -302246192.html

SOURCE SOPHIA GENETICS